Congenital cytomegalovirus, usually shortened to congenital CMV or cCMV, is the most common congenital infection worldwide, affecting roughly 1 in 150 newborns globally. It occurs when a pregnant person passes cytomegalovirus to the fetus, and it is the leading non-genetic cause of childhood hearing loss. Despite its frequency and the seriousness of its potential consequences, awareness among both the public and healthcare providers lags far behind that of other congenital infections, which has slowed progress on screening and early treatment.
How Common It Is and Who Is Most Affected
A large systematic review pooling data from over half a million newborns across countries at every income level estimated the overall birth prevalence of congenital CMV at about 0.67%. That figure hides a striking gap: the rate in lower- and middle-income countries was roughly three times higher than in high-income countries (about 1.4% versus 0.5%).1PubMed Central. Congenital Cytomegalovirus Infection Burden and Epidemiologic Risk Factors in Countries With Universal Screening Individual studies show even wider variation, with birth prevalence ranging from 0.6% in Panama to over 6% in parts of China.2PubMed Central. Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries
The disparity ties back to how widespread CMV already is in a given population. In communities where nearly all women of childbearing age have been exposed to CMV before pregnancy, more pregnancies involve the virus circulating in the mother’s body. Poverty, crowded living conditions, and higher rates of co-infections all push seroprevalence up. Within wealthier countries, racial and socioeconomic disparities persist for the same reasons, making congenital CMV an issue of health equity as much as virology.
How CMV Reaches the Fetus
CMV spreads through bodily fluids: saliva, urine, breast milk, blood, and sexual secretions. For pregnant people, the most common route of exposure is contact with the saliva or urine of young children, who can shed the virus for months or even years after picking it up at daycare. When a person encounters CMV for the first time during pregnancy, known as a primary infection, the risk of the virus crossing the placenta is roughly 1.8 times higher than when someone who already carries CMV experiences a reactivation or catches a new strain, called a nonprimary infection.3PubMed Central. Primary versus nonprimary cytomegalovirus infection during pregnancy, Israel
That distinction matters, but it can also mislead. Because the majority of women in many populations are already seropositive, the bulk of congenital CMV cases worldwide actually come from nonprimary infections. More than 60% of infected newborns are born to mothers who had pre-existing immunity, and studies increasingly report serious outcomes in these babies too.4PubMed. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy The takeaway is that prior immunity reduces risk but does not eliminate it. A mother’s previous exposure to CMV is not a guarantee of protection for the fetus.
At the cellular level, CMV infects placental cells called cytotrophoblasts and can replicate within them. This infection disrupts the cells’ normal ability to differentiate and invade the uterine wall, which is essential for a healthy pregnancy. The placental damage itself may contribute to poor outcomes independent of whether the virus reaches the fetal brain.5PubMed Central. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis
What Congenital CMV Looks Like at Birth
Only about 10 to 15% of babies born with congenital CMV show obvious signs at birth, a group classified as “symptomatic.” The remaining 85 to 90% appear healthy at delivery, which is precisely why the infection so often goes undetected. Among infants with visible symptoms, common findings include an enlarged liver and spleen, low platelet counts, elevated liver enzymes, and abnormalities on brain imaging. In one clinical series, brain MRI detected abnormalities in nearly 9 out of 10 symptomatic infants evaluated, while roughly half had low platelets or elevated liver enzymes.6PubMed. Clinical findings and adverse outcome in neonates with symptomatic congenital cytomegalovirus (SCCMV) infection
Brain injury from congenital CMV appears to involve multiple mechanisms working together. When viral replication is high, the fetus’s own immune response can cause collateral damage as cytotoxic immune cells infiltrate brain tissue. In cases of severe placental infection, the resulting inflammation and tissue death can impair blood flow, leading to oxygen deprivation that adds another layer of harm to the developing brain.7PubMed. Congenital cytomegalovirus infection: patterns of fetal brain damage Timing during pregnancy also matters: infections earlier in gestation tend to cause more widespread damage because the brain is at a more vulnerable stage of development.
The Hidden Burden in “Asymptomatic” Babies
The term “asymptomatic” is somewhat misleading, because many of these seemingly healthy newborns go on to develop problems later. A systematic scoping review found that neurodevelopmental delays or abnormalities are common among children with congenital CMV, particularly those who were symptomatic at birth, but also among those initially classified as asymptomatic.8PubMed Central. Neurodevelopmental Outcomes of Children with Congenital Cytomegalovirus: A Systematic Scoping Review A retrospective cohort study comparing children with and without congenital CMV found that motor delays were diagnosed about eight times more often, cognitive delays about five times more often, and speech-language delays about twice as often in the CMV-positive group.9PubMed. Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study
Hearing loss is perhaps the most studied long-term consequence. By age 18, roughly a quarter of children with asymptomatic congenital CMV had sensorineural hearing loss, compared to about 8% of uninfected controls. Critically, hearing loss can appear or worsen years after birth. Children who already had hearing loss in one ear at birth faced a substantially higher risk of it progressing. However, for children whose hearing was still normal at age five, the risk of developing new hearing loss after that point was not significantly different from uninfected peers.10PubMed Central. Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection Earlier research had already flagged the progressive nature of this hearing loss, with some initially affected infants experiencing further deterioration over their first years of life.11Pediatrics. Progressive Hearing Loss in Infants With Asymptomatic Congenital Cytomegalovirus Infection
The mechanism behind the hearing damage involves CMV infecting cells in the inner ear’s stria vascularis, a structure responsible for maintaining the chemical environment that allows sound signals to travel. When these cells are disrupted, the electrical potential inside the cochlea can break down, leading to sensorineural hearing loss.12PubMed Central. Human fetal inner ear involvement in congenital cytomegalovirus infection Both direct viral damage and the inflammatory response contribute.13PubMed Central. CMV-induced Hearing Loss
Diagnosis and the Screening Debate
Confirming congenital CMV requires detecting the virus in a newborn’s saliva or urine within the first two to three weeks of life. After that window, it becomes difficult to distinguish a congenital infection from one acquired after birth (through breast milk, for example). A meta-analysis of 19 studies covering over 100,000 newborns found that saliva PCR testing had pooled sensitivity around 95% and near-perfect specificity, while dried blood spot (DBS) PCR was considerably less sensitive at around 72%.14PubMed Central. Comparative diagnostic performance of saliva PCR and dried blood spot PCR for congenital cytomegalovirus detection: a systematic review and meta-analysis A head-to-head comparison in a screening setting similarly reported saliva swab sensitivity of about 93% versus roughly 72% for DBS.15American Journal of Obstetrics & Gynecology. Diagnostic performance of saliva PCR versus dried blood spot testing for universal newborn cytomegalovirus screening Saliva testing is also simple and painless, making it more practical for large-scale screening.
During pregnancy, fetal infection can be diagnosed by testing amniotic fluid after about 21 weeks of gestation. When ultrasound results look normal, fetal MRI can sometimes pick up brain abnormalities that ultrasound misses. In a multicenter study of 95 fetuses with confirmed congenital CMV and normal ultrasound results, MRI detected structural abnormalities in about 1 in 10 cases, with higher viral loads in the amniotic fluid predicting a greater chance of finding something on MRI.16PubMed. Role of fetal magnetic resonance imaging in fetuses with congenital cytomegalovirus infection: multicenter study
Despite all of this, most countries do not routinely screen newborns for CMV. Some jurisdictions use targeted screening, testing only babies who fail their newborn hearing screen. Universal screening would catch the larger pool of asymptomatic infections and allow earlier monitoring for delayed-onset hearing loss. Economic analyses consistently find both approaches cost-effective, with universal screening saving more money and preventing more cases of severe hearing loss. One analysis estimated universal screening could save roughly $25 per newborn when the costs of hearing loss-related disability were factored in, compared to about $13 per newborn for targeted screening.17Open Forum Infectious Diseases. A Geographically Weighted Cost-effectiveness Analysis of Newborn Cytomegalovirus Screening Another model estimated that the cost of identifying a single case of hearing loss due to congenital CMV could be as low as about $27,000 through universal screening, and that screening programs could reduce severe hearing loss by anywhere from 4% to 13%.18JAMA Pediatrics. Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection
Treatment After Birth
For newborns with symptomatic congenital CMV, antiviral treatment with valganciclovir is the standard of care. A landmark randomized trial found that six months of treatment was better than six weeks: children treated for the longer course were more likely to have improved or stable hearing at both 12 and 24 months, and they scored higher on language and communication assessments at age two.19PubMed Central. Valganciclovir for symptomatic congenital cytomegalovirus disease Treatment works best when started in the first month of life, which is one of the strongest arguments for early diagnosis.
Valganciclovir is not without side effects. The drug suppresses bone marrow, and neutropenia is the most common complication. In one study of 160 treated infants, about 29% experienced at least one episode of low neutrophil counts, with most episodes occurring during the first three months. Roughly 6% had severe neutropenia. Anemia requiring blood transfusion occurred in a small number of cases, though no long-term adverse events were recorded.20PubMed. Hematologic Adverse Events Associated With Prolonged Valganciclovir Treatment in Congenital Cytomegalovirus Infection In preterm and low birth-weight infants, the rates may be even higher, with nearly half developing neutropenia and many experiencing more than one type of blood-count problem in the first four weeks.21PubMed Central. Dosing, Toxicity and Drug Concentrations for Ganciclovir/Valganciclovir in Preterm and Low Birthweight Infants Treated for Cytomegalovirus Regular blood monitoring is essential throughout treatment.
Whether to treat asymptomatic babies who test positive remains a thornier question. The clearest benefit of antivirals has been demonstrated in symptomatic disease, and the side effects carry real weight for a baby who currently seems healthy. Clinical practice is evolving, with some centers offering treatment to asymptomatic infants who show signs of hearing loss, but this is not yet universally recommended.
Prenatal Prevention
Given that no approved vaccine exists, prevention during pregnancy currently relies on hygiene and, in some cases, antiviral medication. The primary hygiene advice is straightforward: avoid sharing utensils with young children, wash hands thoroughly after changing diapers or wiping a child’s nose, and avoid kissing toddlers on the mouth. These recommendations come from expert bodies including the American College of Obstetricians and Gynecologists.22PubMed Central. Washing our hands of the congenital cytomegalovirus disease epidemic A systematic review of hygiene-based interventions during pregnancy found that they do reduce the risk of acquiring CMV, though adherence is challenging in practice, especially for mothers of young children.23PubMed Central. Hygiene-based measures for the prevention of cytomegalovirus infection in pregnant women: a systematic review
For women who are diagnosed with a primary CMV infection during pregnancy, two interventions have been studied to try to prevent transmission to the fetus: the antiviral drug valacyclovir and CMV-specific hyperimmune globulin (HIG). A systematic review found that valacyclovir as a preventive strategy had the strongest evidence behind it, supported by a well-conducted randomized controlled trial, while the evidence for HIG was more mixed, with randomized trials failing to confirm the benefit suggested by observational data.24PubMed. Describing the Impact of Maternal Hyperimmune Globulin and Valacyclovir on the Outcomes of Cytomegalovirus Infection in Pregnancy: A Systematic Review Some clinical series have reported better outcomes with HIG in specific settings, including lower rates of viral positivity and abnormalities at follow-up compared to valacyclovir-treated groups, but these were observational comparisons rather than randomized trials.25PubMed Central. Prevention of Congenital Cytomegalovirus Infection: Review and Case Series of Valaciclovir versus Hyperimmune Globulin Therapy The field has not settled on a single best approach, and practice varies by country and institution.
The Awareness Gap
One of the most frustrating aspects of congenital CMV is how little the public knows about it. A semi-systematic review of studies on pregnant patients’ awareness found that only about 38% had been educated about congenital CMV, making it the least discussed of the major congenital infections.26PubMed Central. Awareness of Pregnant Patients about Congenital Cytomegalovirus Infection—A Semi-Systematic Review By contrast, conditions like toxoplasmosis and Zika tend to be more widely recognized despite affecting fewer newborns in most high-income settings.
The financial burden underscores why this gap matters. The estimated annual economic cost of congenital CMV in the United Kingdom alone was about £732 million in 2016, with roughly 60% of that coming from indirect costs like lost productivity. Long-term impairments drove far more cost than the acute management of the infection at birth.27PubMed. Economic cost of congenital CMV in the UK In Germany, the lifetime cost per affected child has been estimated at over $1.3 million. Most of those costs trace to autism spectrum disorder, cerebral palsy, hearing loss, and epilepsy as long-term sequelae.28PubMed Central. Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies
Vaccine Progress
A CMV vaccine has been on the wish list of infectious disease researchers for decades, and development has been slower than for many other viral vaccines. Multiple candidate approaches are in various stages of clinical trials: protein-based vaccines targeting the virus’s envelope, DNA-based vaccines expressing immune targets, and live-attenuated or replication-defective virus designs.29Journal of Virus Eradication. Cytomegalovirus vaccines under clinical development A 2024 expert meeting reviewing the field concluded that a safe and effective vaccine appears to be within reach, though challenges remain in designing clinical trials that can demonstrate efficacy against congenital infection specifically.30PubMed Central. A vaccine against cytomegalovirus: how close are we? One complication is that natural infection does not produce fully protective immunity, as the sheer number of nonprimary cases demonstrates. A vaccine would need to do better than the immune response from natural infection, which is a high bar.
Why CMV Is So Hard to Eradicate
Part of what makes a vaccine so difficult is that CMV has evolved an extraordinary toolkit for dodging the immune system. The virus hides in precursor blood cells and certain white blood cells, entering a dormant state called latency. While hiding, it actively interferes with the body’s ability to detect it. It blocks the pathways cells use to signal the presence of an invader, reduces the display of viral fragments on cell surfaces so that immune cells cannot recognize infected cells, and even produces proteins that mimic the body’s own immune-calming molecules. When the immune system tries to compensate by deploying natural killer cells, the virus counters with proteins that engage those cells’ “off switches.”31PubMed Central. The Immunoregulatory Mechanisms of Human Cytomegalovirus from Primary Infection to Reactivation It also blocks programmed cell death, the normal process by which a compromised cell sacrifices itself to stop viral spread.32PubMed. Molecular mechanisms and targets underlying immune evasion by human cytomegalovirus This layered evasion strategy is why CMV persists for life in virtually everyone who catches it, and why reactivation during pregnancy remains a risk even in seropositive women.
Congenital CMV and HIV
CMV and HIV have a complicated relationship during pregnancy. Among HIV-infected infants in one large study, 18% also had congenital CMV, compared to about 5% of infants who were exposed to maternal HIV but did not become HIV-infected themselves. Infants who acquired HIV in the womb had the highest rates of congenital CMV, with about 23% co-infected, translating to a six-fold greater odds compared to HIV-exposed but uninfected babies.33PubMed Central. Congenital CMV and HIV Perinatal Transmission This likely reflects the way HIV weakens the immune control that would normally keep CMV in check during pregnancy. Even among mothers who are already CMV-seropositive, having HIV increases the chance of transmitting CMV to the baby.34The Journal of Infectious Diseases. Maternal Antibody Responses and Nonprimary Congenital Cytomegalovirus Infection of HIV-1–Exposed Infants What happens to these co-infected children over the long term is still being studied, but the interaction between the two viruses is concerning enough that CMV screening in HIV-exposed pregnancies deserves particular attention.35PubMed Central. Cytomegalovirus and HIV Co-Infections During Pregnancy and Early Childhood
Life as an Adult After Congenital CMV
Most of the research on congenital CMV focuses on early childhood, and comparatively little is known about how affected individuals fare in adulthood. One study that tracked adults with asymptomatic congenital CMV found no significant difference in self-reported quality of life compared to uninfected peers, even among those with hearing loss.36PubMed Central. The Impact of Asymptomatic Congenital Cytomegalovirus on Adult Quality of Life That is reassuring as far as it goes, though the study focused on people with asymptomatic infection, who represent the milder end of the spectrum. Adults with symptomatic congenital CMV and more significant neurological involvement likely face different challenges, but long-term follow-up data for this group remain sparse. For parents of a newly diagnosed baby, the research does suggest that many children, particularly those in the asymptomatic category, adapt well over time, though ongoing hearing monitoring throughout childhood remains important given the risk of delayed-onset or progressive loss.